<SEC-DOCUMENT>0001104659-25-040399.txt : 20250819
<SEC-HEADER>0001104659-25-040399.hdr.sgml : 20250819
<ACCEPTANCE-DATETIME>20250428202056
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-25-040399
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		300 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-430-5595

	MAIL ADDRESS:	
		STREET 1:		300 FIFTH AVENUE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLYCOMIMETICS INC
		DATE OF NAME CHANGE:	20030711
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt"><BR>
<IMG SRC="tm256615d12_correspimg001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 39%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">Sidley Austin LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">787 Seventh Avenue</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">New York, NY 10019</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">+1 212 839 5300</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">+1 212 839 5599 Fax</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">AMERICA
    </FONT><FONT STYLE="text-transform: uppercase">&bull; <FONT STYLE="font-family: Times New Roman, Times, Serif">ASIA PACIFIC </FONT>&bull;
    <FONT STYLE="font-family: Times New Roman, Times, Serif">EUROPE</FONT></FONT></P></TD>
    <TD STYLE="width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Via EDGAR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549-3628</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Jessica Dickerson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GlycoMimetics,&nbsp;Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment No.&nbsp;1 to Registration Statement on Form&nbsp;S-4</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed April&nbsp;4, 2025</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File No.&nbsp;333-285035</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of GlycoMimetics,&nbsp;Inc. (the &ldquo;<U>Company</U>&rdquo;),
we are submitting this letter to the Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;) via EDGAR in response to the comment
letter from the staff of the SEC (the &ldquo;<U>Staff</U>&rdquo;), dated April&nbsp;22, 2025, pertaining to the Company&rsquo;s above-referenced
Amendment No.&nbsp;1 to Registration Statement on Form&nbsp;S-4 (the &ldquo;<U>Registration Statement</U>&rdquo;). In connection with
such responses, the Company is concurrently filing Amendment No.&nbsp;2 to the Registration Statement (the &ldquo;<U>Second Amended Registration
Statement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For your convenience, the Staff&rsquo;s comments
are summarized in this letter, and each comment is followed by the applicable responses on behalf of the Company. Unless otherwise indicated,
page&nbsp;references in the responses correspond to the page&nbsp;numbers in the Second Amended Registration Statement. Capitalized terms
used in this letter but otherwise not defined herein shall have the meanings set forth in the Second Amended Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Registration Statement on Form&nbsp;S-4</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cover Page</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your revisions in response to prior comment 1. Please tell us how your disclosure in the
third paragraph on the second page&nbsp;of your cover page&nbsp;regarding the number of securities you are offering ties to the fee table
(where it appears you are registering the offering of fewer shares of common stock than disclosed) or revise your disclosure or fee table
as appropriate.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on the Cover
Page, page iv,&nbsp;and in the fee table of the Second Amended Registration Statement in response to the Staff&rsquo;s comment and to reflect expectations
as of April&nbsp;15, 2025 regarding the number of securities to be offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Questions and Answers about the Merger</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>What are the U.S. federal income tax considerations
of the Cayman..., page&nbsp;xi</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your statement that you intend that the Cayman Redomestication qualify as a &ldquo;reorganization&rdquo;
within the meaning of Section&nbsp;368(a)&nbsp;of the Code and that, assuming it so qualifies, a U.S. Holder of Combined Company stock
will not recognize gain or loss upon the Cayman&nbsp;Redomestication. Please file an appropriate tax opinion regarding this intended tax
treatment as an exhibit to the registration statement. Refer to Item 601(b)(8)&nbsp;of Regulation S-K and Section&nbsp;III of Staff Legal
Bulletin No.&nbsp;19 (CF), available on our website.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has filed a form of tax opinion of Gibson,
Dunn&nbsp;&amp; Crutcher LLP, counsel to Crescent, regarding the tax treatment of Cayman Redomestication as Exhibit 8.1 to the Second Amended
Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Prospectus Summary</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>The Companies</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Crescent, page&nbsp;1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your disclosure that Crescent intends to submit an Investigational New Drug application
to the FDA for CR-001 in the fourth quarter of 2025. We also note from the disclosure on page&nbsp;280 that it appears that Crescent intends
the Phase 1 trial to be open to &ldquo;solid tumor all-comers.&rdquo; Please specify here, and in other locations where appropriate, what
indication(s)&nbsp;Crescent anticipates its&nbsp;IND will specify. In this regard, we note your disclosure that ivonescimab demonstrated
significantly improved progression-free survival compared to pembrolizumab in the HARMONi-2 trial where the indication was for the treatment
of na&iuml;ve advanced and metastatic NSCLC. If Crescent&rsquo;s anticipated Phase 1 trial will study a broader indication than the HARMONi-2
trial, please clarify in an appropriate location any risks from pursuing a broader indication.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 2 and 285
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment. The Company further respectfully advises the Staff that Crescent continues to evaluate specific indications to designate in its IND for
CR-001. Crescent expects to identify specific indications for inclusion in the IND closer in time to the submission date of the IND, but
after the effectiveness of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;3</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>Please continue revising your disclosure in response to prior comment 8 to further clarify the current
state of Crescent's business. Specifically, please clarify what you mean on pages&nbsp;2, 273 and 322 when you state that Crescent is
 &ldquo;advancing&rdquo; its expected second and third programs, CR-002 AND CR-003. In this regard, we note your disclosure that Crescent
has not exercised the option for CR-002 and has not entered into an option agreement for CR-003.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 2, 278 and 329
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your response to prior comment 9. If true, please further revise your disclosure to clarify
that Crescent&rsquo;s intent to seek regulatory approvals for CR-001 to treat multiple solid tumor indications is subject to successful
completion of clinical trials, which have not yet commenced, and that it will be several years before Crescent will be able to commercialize
CR-001, assuming it is able to successfully complete clinical trials and obtain the requisite regulatory approvals.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 1, 277, 278, 282 and 329
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your response to prior comment 10, and we reissue the comment in part. Briefly describe
the influence, if any, that Fairmount and Paragon may have over any decision by Crescent to exercise the options and in negotiating the
terms of the respective&nbsp;licensing agreements. In this regard, in addition to the relationship between Crescent, Paragon, Fairmount
and Parascent, we note the affiliation of two of your directors with Fairmount and the rights of preferred stockholders to elect directors
with superior voting rights.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 2, 106 and 354
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Risk Factors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Risks Related to the Combined Company, page&nbsp;95</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>To the extent appropriate, please revise your risk factors in this section to distinguish between
risks related to the Combined Company before and after the Cayman Redomestication. For example only, we note some of these risk factors
address provisions of Delaware law and the Combined Company&rsquo;s certificate of incorporation and bylaws under Delaware law without
acknowledging that such law and documents will no longer govern the Combined Company following the Cayman Redomestication.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 15, 96-97 and 103-105
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;4</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>The Merger</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Crescent Restricted Stock Units, page&nbsp;144</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your disclosure that each restricted stock unit representing the right to receive shares
of Crescent common stock will be converted into restricted stock units representing the right to receive shares of GlycoMimetics common
stock. Please revise your disclosures on the prospectus cover page, in the &ldquo;Explanatory Note&rdquo; and elsewhere (e.g., on pages&nbsp;iii,
iv and vi) as appropriate to reflect this exchange or otherwise advise.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure throughout
the Second Amended Registration Statement, including on the Cover Page, in the Explanatory Note,&nbsp;and pages iii, iv, vi and viii, in response to the Staff&rsquo;s comment and to reflect expectations as of
April&nbsp;15, 2025 regarding the number of securities to be offered and the amendment of the merger agreement to convert Crescent
restricted stock units into GlycoMimetics restricted stock units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>GlycoMimetics Directors, Officers and Corporate
Governance, page&nbsp;174</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>Please clarify in this section that Brian Hahn ceased employment with you in February&nbsp;2025
and now serves as your Principal Executive and Financial Officer in his capacity as a consultant. In this regard, we note your disclosure
on page&nbsp;184 regarding these arrangements.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page&nbsp;180
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>GlycoMimetics Executive Compensation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Executive Officer Separation and Consulting
Agreements, page&nbsp;184</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your disclosure regarding separation and consulting agreements you entered into with each
of Harout Semerjian and Brian Hahn. Please file these agreements as exhibits to the registration statement. Refer to Item 601(b)(10)(iii)(A)&nbsp;of
Regulation S-K.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has filed the requested agreements as Exhibits 10.30-10.33
to the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Crescent Executive Compensation, page&nbsp;192</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>11.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>Please identify Jonathan Violin as one of Crescent's named executive officers for the 2024 fiscal
year and revise your officer and director compensation disclosures accordingly. Refer to Item 402(m)(2)(i)&nbsp;of Regulation S-K, which
specifies that all individuals serving as the principal executive officer during the last completed year are named executive officers.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages
197-200 of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;5</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Crescent's Business, page&nbsp;272</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>12.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>Please continue revising your disclosure in this section in response to prior comment 21 to remove
statements that may imply that a product candidate is safe or effective as such determinations are solely within the authority of the
FDA and corresponding regulatory authorities. For example only, we note your statement on page&nbsp;277 that &ldquo;[t]he design of ivonescimab
drives its effectiveness&rdquo; as well as your reference to &ldquo;increased effectiveness&rdquo; on the same page.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 282, 283 and 286
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>13.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>Refer to the&nbsp;WuXi&nbsp;Biologics MSA&nbsp;and Charles River MSA agreements described on pages&nbsp;285-287.&nbsp;For
each of these agreements, please revise to disclose the&nbsp;amounts and dates of any consideration or fees exchanged&nbsp;related to
these agreements, and disclose the extent to which any&nbsp;work orders have commenced pursuant to these agreements.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 292 and 293
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>The design of CR-001, page&nbsp;278</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>14.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your revised disclosure in response to prior comment 26 that, pursuant to the Paragon Option
Agreements, Crescent holds options to acquire the intellectual property rights to the composition of matter claims filed by Paragon for
the CR-001 sequence. If true, please revise your disclosure to clarify that Crescent has exercised its option for these intellectual property
rights and expects to enter into a license agreement with Paragon for the same prior to effectiveness of the registration statement. Alternatively,
clarify whether such intellectual property is subject to options other than the option already exercised by Crescent.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page
283 of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>In vitro activity, page&nbsp;278</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>15.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your response to prior comment 27. Please further revise your disclosure to provide the
p-value for the data presented in the second graph in this section or otherwise advise.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page
284 of the Second Amended Registration Statement in response to the Staff&rsquo;s comment to clarify that the p-value relates solely to the data presented in the graph on the left in this section, and that the increase in binding
reflected in the graph on the right in this section was not statistically significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;6</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical potential for CR-001, page&nbsp;279</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>16.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your response to prior comment 28. Specifically, we note that you now refer to the potential
for CR-001 to receive &ldquo;first-in-class&rdquo; approval in select indications. Given Crescent&rsquo;s early stage of development and
the length of the drug development process, such characterization appears to be premature. Accordingly, please remove the statement or
otherwise advise.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page&nbsp;285
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Planned clinical development of CR-001,
page&nbsp;279</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>17.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your response to prior comment 29. Please further revise your disclosure to disclose
                                                                                                                                   the &ldquo;other jurisdictions&rdquo; where Crescent intends to conduct its proposed Phase 1 clinical trial for CR-001.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on page&nbsp;285
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Management Following the Merger, page&nbsp;342</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>18.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>Although we note your revisions in response to prior comment 35, given that each Preferred Director
shall be entitled to three votes on each matter presented to the board of directors, please disclose whether those provisions will effectively
give the Preferred Directors control over decisions to be made by the board following the merger and include risk factor disclosure as
appropriate. In this regard, we note that it appears from your current disclosure that each of the four non-Preferred Directors will have
one vote and that each of the two Preferred Directors will have three votes, such that of the total of 10 votes, the Preferred Directors
would have 6 votes and may have effective control over decisions to be made by the board following the merger.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that it has revised the disclosure on pages 2, 106 and&nbsp;354
of the Second Amended Registration Statement in response to the Staff&rsquo;s comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;7</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Executive Officers and Directors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Director Independence, page&nbsp;346</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>19.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>We note your disclosure that you expect that the Combined Company's board of directors will determine
that Peter Harwin is an independent director under Nasdaq listing rules. We further note your disclosure on page&nbsp;344 that Peter Harwin
co-founded and is a Managing Member at Fairmount. With a view toward disclosure, please tell us whether, and if so, how, you expect this
relationship to impact the independence determination with respect to Peter Harwin, particularly considering Nasdaq Listing Rule&nbsp;5605(a)(2)(D).
In this regard, we note the related party disclosures regarding both Fairmount and Paragon. If Mr.&nbsp;Harwin would not be considered
an independent director, given that each Preferred Director, including Mr.&nbsp;Harwin, will be entitled to three votes on each matter
presented to the board of directors, please tell us whether the Combined Company would have a majority independent board.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that Crescent has advised the Company that Crescent
has reviewed and assessed the independence of Peter Harwin under the standards for assessing director independence set forth in the Nasdaq
listing standards. As a result of this review and assessment, which took into account the information provided by Mr.&nbsp;Harwin concerning
his background, employment and affiliations, and all other facts and circumstances that Crescent deemed relevant, and after consulting
with counsel, Crescent believes that Mr.&nbsp;Harwin does not have a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director and therefore expects the Combined Company&rsquo;s board of directors to determine
that Mr.&nbsp;Harwin qualifies as an &ldquo;independent director&rdquo; under Nasdaq listing standards. Specifically, Crescent considered,
among other things, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Fairmount&rsquo;s stock ownership in Crescent and the Combined Company, disclosed or will be disclosed
under &ldquo;Principal Stockholders of Crescent&rdquo; and &ldquo;Principal Stockholders of the Combined Company&rdquo; beginning on pages&nbsp;394
and 396, respectively, of the Second Amended Registration Statement does not preclude a finding of Mr.&nbsp;Harwin&rsquo;s independence
under Nasdaq Listing Rule&nbsp;5605(a)(2)&nbsp;as &ldquo;&hellip;Nasdaq does not believe that ownership of Company stock by itself &hellip;
preclude[s] a board finding of independence&rdquo; (see Nasdaq IM-5605). In addition, after consummation of the Merger, Fairmount is expected
to beneficially own 19.99% of Combined Company, and the Combined Company will not be an entity that is consolidated into Fairmount&rsquo;s
financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">transactions between Crescent, on the one hand, and Fairmount, on the other hand, disclosed under &ldquo;Certain
Relationships and Related Party Transactions of the Combined Company&mdash;Crescent Transactions&rdquo; beginning on page&nbsp;358
of the Second Amended Registration Statement do not preclude a finding of Mr.&nbsp;Harwin&rsquo;s independence under Nasdaq Listing Rule&nbsp;5605(a)(2)(D)&nbsp;because
the payments made pursuant to such transactions are &ldquo;payments arising solely from investments in [Crescent&rsquo;s] securities&rdquo;
(see Nasdaq Listing Rule&nbsp;5605(a)(2)(D)); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">transactions between Crescent, on the one hand, and Paragon, on the other hand, disclosed under &ldquo;Certain
Relationships and Related Party Transactions of the Combined Company&mdash;Crescent&rsquo;s Relationships with Paragon, Parascent and
Fairmount&rdquo; beginning on page&nbsp;359 of the Second Amended Registration Statement do not preclude a finding of Mr.&nbsp;Harwin&rsquo;s
independence under Nasdaq Listing Rule&nbsp;5605(a)(2)(D)&nbsp;because (a)&nbsp;Mr.&nbsp;Harwin has served only as a director at each
of Crescent and Paragon since Crescent&rsquo;s inception and (b)&nbsp;Mr.&nbsp;Harwin has not served as, and has not had a family member
who has served as, a partner, controlling shareholder or an executive officer of Crescent or Paragon since Crescent&rsquo;s inception.
Therefore, notwithstanding Mr.&nbsp;Harwin&rsquo;s role as a Managing Member at Fairmount, Nasdaq Listing Rule&nbsp;5605(a)(2)(D)&nbsp;does
not apply to payments made by Crescent to Paragon or received by Crescent from Paragon for the purpose of assessing Mr.&nbsp;Harwin&rsquo;s
independence.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;8</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>General</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>20.</B></FONT></TD><TD STYLE="text-align: justify"><B><I>It appears that you intend to change the jurisdiction of incorporation of the Combined Company from
Delaware to the Cayman Islands after effectiveness. Please tell us whether the Cayman Islands entity intends to file a post-effective
amendment to the Form&nbsp;S-4 expressly adopting it as its own registration statement for all purposes under the Securities Act and the
Securities Exchange Act. Refer to Securities Act Rule&nbsp;414.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Response</U></FONT>:
The Company respectfully acknowledges the Staff&rsquo;s comment and advises the Staff that, if the Cayman Redomestication is approved
and effected, the Cayman Islands entity intends to file a post-effective amendment to the Form&nbsp;S-4 expressly adopting it as its own
registration statement for all purposes under the Securities Act and the Securities Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>*****</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;9</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please contact the undersigned at 410-559-2881
or via email at arubin@sidley.com if you have any questions with respect to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Asher M. Rubin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asher
    M. Rubin,&nbsp;Esq.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sidley Austin LLP</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Hahn, <I>GlycoMimetics,&nbsp;Inc.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John H. Butler,&nbsp;Esq., <I>Sidley Austin LLP</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kostian Ciko,&nbsp;Esq., <I>Sidley Austin LLP</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan A. Murr, <I>Gibson, Dunn&nbsp;&amp; Crutcher LLP</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Branden C. Berns, <I>Gibson, Dunn&nbsp;&amp; Crutcher LLP</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm256615d12_correspimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm256615d12_correspimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  N ) # 2(  A$! Q$!_\0
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M<-NGN8Q)*V,9<Q+N/YYKU#X,?\DDT'_=F_\ 1SUYQ\==*70O 'A#24?>+/\
M<;_[VV-1G\<5Z/\ !C_DDF@_[LW_ *.>@#O*^3OCH_E_%JY<C(6& X_X"*^L
M:^3_ (X@-\7;A2,@Q6X(_P" B@#T'_AI31O^A?O_ /OZE;GA#XWZ9XO\46>A
M6^CW=O+=;]LLDBE5VHS\@?[M=3_PK3P3_P!"OIG_ 'X%6]-\#^%]'OXK_3M!
ML+6[BSLFBA"LN00<'Z$C\: -N>"&ZMY+>XB26&52CQNH964\$$'J*^5?$%E?
M_!KXL1WMB)%TYY/.@56.)K<GYXB>Y'3GT4^E?5U>(_M)QH?#6BRE09%O&4-C
MD IR/T'Y4 <5\-]"O/B?\3;KQ'K,?FV-O-]IN-_*LW_+.(>H&!QZ+CO7U'7F
MGP'@BB^%=E)'&JO-/,\C 8+D.5R?7@ ?A7I= 'DOQLT+QGJ^C12:',);"VE$
M\EK:JRSDJ!M;.?GP=QP,$<<'&1YO9?'OQMHUH+"_L[.YN(QM$MY ZR_\" 89
M_(5]14A5202H)'0D4 ?+?A+P1XF^*'C3_A(_$$,L5@TRRW$\L902JN,1Q@]1
M@ 9Z >_7L/VC=,O]1'AO[#97-SL^T[_(B9]N?*QG XZ&O=:* /#_ !'IM])^
MS1IMDEE<M=K';Y@6)BXP_/RXS7F?A/Q-\0O!>FS6&C:7=QV\LQF82:<SG<0!
MU(]%%?7E% 'RI=W'Q<^(Q%A-;ZG]F/#((/LL)!Z[CA0WT)->H?##X,)X.OTU
MO6+J.[U14(ABB'[N D8)R>6;'&<#&3UZUZW10!XM^T3IU[J&B:(ME9W%RR7,
MA80Q,Y VCK@5YKH/C;XF^&]%MM(TRQNX[.W#"-6TPL1EBQY*YZDU]9T4 ?-_
MA[XD_%&\\2Z5:WUM<"TFO(8YR=,V@(7 ;G;QP3S67\;='U:Z^*-U<V>F7D\8
MAAVR16[.N0H[@8KZDHH ^7O^%I?%O_GUN?\ P5?_ &-6]*^)GQ5N-8LH+FVN
M!!)<1I(3I>/E+ 'G;QQ7TM10 5XY^T/I][J'AC2$LK2XN76\)988RY V'DX%
C>QT4 >??!2UN++X7:=!=6\L$RR39CE0JPS(W8UZ#110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
